Marshall Wace’s NEVRO CORP. NVRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-31,842
Closed -$809K 2782
2023
Q2
$809K Sell
31,842
-77,539
-71% -$2.24M ﹤0.01% 1810
2023
Q1
$3.95M Buy
109,381
+7,419
+7% +$261K 0.01% 1113
2022
Q4
$4.04M Sell
101,962
-84,349
-45% -$3.51M 0.01% 1329
2022
Q3
$8.68M Sell
186,311
-490,779
-72% -$22.8M 0.02% 983
2022
Q2
$29.7M Buy
677,090
+220,384
+48% +$12.1M 0.06% 330
2022
Q1
$33M Buy
456,706
+295,914
+184% +$21.3M 0.06% 340
2021
Q4
$13M Buy
160,792
+139,772
+665% +$14M 0.02% 687
2021
Q3
$2.45M Buy
+21,020
New +$2.75M 0.01% 1409
2021
Q1
Sell
-9,630
Closed -$1.67M 2933
2020
Q4
$1.67M Buy
+9,630
New +$1.56M 0.01% 1023
2019
Q2
Sell
-6,024
Closed -$376K 1928
2019
Q1
$376K Sell
6,024
-20,019
-77% -$941K ﹤0.01% 1212
2018
Q4
$1.01M Sell
26,043
-3,975
-13% -$177K 0.01% 911
2018
Q3
$1.71M Buy
+30,018
New +$1.88M 0.01% 711
2017
Q3
Sell
-5,906
Closed -$437K 431
2017
Q2
$437K Buy
+5,906
New +$473K 0.02% 249
2016
Q4
Sell
-63,140
Closed -$6.59M 1144
2016
Q3
$6.59M Buy
+63,140
New +$5.7M 0.05% 348
2015
Q2
Sell
-49,194
Closed -$2.36M 1073
2015
Q1
$2.36M Buy
49,194
+22,692
+86% +$985K 0.03% 443
2014
Q4
$1.02M Buy
+26,502
New +$834K 0.01% 563

Other funds holding NVRO

Marshall Wace's NVRO Position: Q3 2023 in Review

Marshall Wace sold out of NEVRO CORP. (NVRO) in Q3 2023, closing a stake of 31,842 shares — an estimated $809K sold.

Marshall Wace first reported a position in NVRO in Q4 2014 and held it in 16 quarters. The position peaked at $33M in Q1 2022. 136 funds tracked by Wall St. Rank hold NVRO as of Q3 2023.

  • Marshall Wace reported no remaining NEVRO CORP. position as of Q3 2023 after selling out during the quarter.
  • Marshall Wace sold 31,842 NEVRO CORP. shares in Q3 2023, an estimated $809K.
  • Marshall Wace first reported a position in NEVRO CORP. in Q4 2014 and held it in 16 quarters.
  • Marshall Wace's NEVRO CORP. position peaked at $33M in Q1 2022.
  • 136 funds tracked by Wall St. Rank held NEVRO CORP. as of Q3 2023.

Based on Marshall Wace's 13F filing for Q3 2023, filed 14 Nov 2023.